H.R. 2666 118th Congress
Medicaid VBPs for Patients Act
- Health
- Sponsor: Rep. Guthrie, Brett [R-KY-2]
- Congress.gov ↗
Latest action, Dec 19, 2024: Placed on the Union Calendar, Calendar No. 768.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
42 cosponsors
Sponsored by Rep. Guthrie, Brett [R-KY-2] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
20 D · 22 R
Referred to: House: Energy and Commerce Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
8 reports
ACADEMY OF MANAGED CARE PHARMACY
TIBER CREEK GROUP
7 reports
7 reports
7 reports
CSL BEHRING LLC
THE NICKLES GROUP, LLC
7 reports
GENETIX BIOTHERAPEUTICS, INC.
ARNOLD & PORTER KAYE SCHOLER LLP
7 reports
JOHNSON & JOHNSON SERVICES, INC.
THE NICKLES GROUP, LLC
7 reports
7 reports
7 reports
7 reports
SPARK THERAPEUTICS, INC.
JEFFREY J. KIMBELL & ASSOCIATES, INC.
7 reports
7 reports
All 25 of 48 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ACADEMY OF MANAGED CARE PHARMACY | 8 | $1.1M | Q1 2023 | Q3 2024 | yes | |
| ACADEMY OF MANAGED CARE PHARMACY | TIBER CREEK GROUP | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 7 | $20.1M | Q4 2023 | Q3 2024 | yes | |
| BIOMARIN PHARMACEUTICAL INC. | 7 | $2.2M | Q4 2023 | Q3 2024 | yes | |
| CALIFORNIA HOSPITAL ASSOCIATION | 7 | $2.7M | Q4 2023 | Q3 2024 | yes | |
| CSL BEHRING LLC | THE NICKLES GROUP, LLC | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| GENETIX BIOTHERAPEUTICS, INC. | ARNOLD & PORTER KAYE SCHOLER LLP | 7 | $400K | Q4 2023 | Q3 2024 | yes |
| JOHNSON & JOHNSON SERVICES, INC. | THE NICKLES GROUP, LLC | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| MERCK & CO INC | 7 | $16.2M | Q4 2023 | Q3 2024 | yes | |
| NOVARTIS | 7 | $9.2M | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $50.1M | Q4 2023 | Q3 2024 | yes | |
| PTC THERAPEUTICS, INC. | 7 | $1.3M | Q4 2023 | Q3 2024 | yes | |
| SPARK THERAPEUTICS, INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| SPARK THERAPEUTICS, INC. | 7 | $1.4M | Q4 2023 | Q3 2024 | yes | |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | 7 | $13.5M | Q4 2023 | Q3 2024 | yes | |
| UCB, INC. | THE NICKLES GROUP, LLC | 7 | $420K | Q4 2023 | Q3 2024 | yes |
| ALLIANCE FOR REGENERATIVE MEDICINE | 6 | $1.1M | Q4 2023 | Q3 2024 | yes | |
| ALLIANCE FOR REGENERATIVE MEDICINE | HOLLAND & KNIGHT LLP | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 6 | $6.7M | Q2 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | THE MCMANUS GROUP | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| BLUEBIRD BIO, INC. | 5 | $670K | Q4 2023 | Q2 2024 | yes | |
| ORCHARD THERAPEUTICS NORTH AMERICA | THE MCMANUS GROUP | 5 | $300K | Q1 2023 | Q1 2024 | yes |
| ALLIANCE FOR REGENERATIVE MEDICINE | AVENUE SOLUTIONS | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| ASTELLAS PHARMA US, INC. | 4 | $3.1M | Q1 2024 | Q3 2024 | yes | |
| ASTRAZENECA PHARMACEUTICALS LP | 4 | $3.1M | Q4 2023 | Q3 2024 | yes |